

Calcitonin

Class: Antidote, Hormone

Indications: Treatment of symptomatic Paget's disease of bone, adjunctive therapy for hypercalcemia; treatment of osteoporosis in women >5 years postmenopause.

Available dosage form in the hospital: (50 IU, 100 IU) Amp, 200 IU Nasal Spray.

Trade Names:

Dosage:

Paget's disease, symptomatic: I.M., S.C.: Initial: 100 units daily; maintenance: 50 units every 1-2 days; may be preferable to maintain doses of 100 units daily for serious deformity or neurologic involvement for not more than 3 months unless pathologic fractures.

Hypercalcemia Initial: I.M., S.C.: 4 units/kg every 12 hours; after 1-2 days, may increase up to 8 units/kg every 12 hours; if the response remains unsatisfactory after 2 more days, may further increase up to a maximum of 8 units/kg every 6 hours

Postmenopausal osteoporosis: 100 units every other day S.C. or Intranasally 200 units (1 spray) in one nostril daily

Common side effect:

Respiratory: Rhinitis (Intranasally), Nasal mucosa ulcer, bronchospasm, flu-like symptoms, URTI.

Cardiovascular: Flushing, angina pectoris, hypertension.

Central nervous system: Depression, dizziness, fatigue.

Dermatologic: Erythematous rash

Gastrointestinal: Nausea, abdominal pain, constipation, diarrhea, dyspepsia.

Genitourinary: Cystitis

Hematologic & oncologic: Lymphadenopathy.

Infection: Increased susceptibility to infection.

Local: Injection site reaction (injection)

Neuromuscular & skeletal: Back pain, osteoarthritis, myalgia, paresthesia

Ophthalmic: Conjunctivitis, abnormal lacrimation

Pregnancy Risk Factor: C